Acute Brachial Arterial Embolic Occlusion Following Anticoagulant Discontinuation in a Renal Biopsy of a Nephrotic Syndrome Patient

Tomoki Taniguchi, Mayumi Tomita, Hiroyuki Ikeda, Ryo Kamimatsuse, Kojiro Yamamoto, Ai Shimizu, Yuko Yanai, Tadashi Kamata and Noriyuki Iehara

Abstract:
A 73-year-old woman with atrial fibrillation treated with rivaroxaban was hospitalized for nephrotic syndrome. After discontinuation of rivaroxaban to lower the risk of hemorrhagic events, a renal biopsy was performed. Rivaroxaban was scheduled to resume a week after the biopsy to prevent renal hemorrhaging. However, she developed acute brachial arterial embolic occlusion and mural thrombosis in the abdominal aorta before resuming rivaroxaban. If immune-mediated renal diseases are suspected in anticoagulated patients at a risk of thrombotic events, physicians should consider initiating glucocorticoid therapy without a renal biopsy in order to avoid hemorrhagic and thrombotic events.

Key words: renal biopsy, nephrotic syndrome, atrial fibrillation, anticoagulant discontinuation, thromboembolism

Introduction
Renal biopsies are essential procedures for determining the diagnosis, prognosis, and treatment of patients with kidney disease. Most complications of renal biopsies are associated with bleeding (1). Major hemorrhagic complications include massive bleeding requiring angiographic intervention, massive transfusion, and nephrectomy, while minor complications include self-limited anemia, gross hematuria, and perinephric hematoma (1, 2). Therefore, periprocedural anticoagulant discontinuation is required when patients who have taken anticoagulants undergo a biopsy. While coagulopathy is rare as a complication of a renal biopsy (3, 4), these patients are at risk of thromboembolism due to anticoagulant discontinuation during renal biopsies.

We herein report a case of nephrotic syndrome in which periprocedural anticoagulant discontinuation contributed to acute brachial arterial embolic occlusion following a renal biopsy.

Case Report
A 73-year-old woman was hospitalized for nephrotic syndrome. Her medical history included atrial fibrillation (AF) with a CHADS2 score of 1 treated with rivaroxaban. A urine protein level of 3+ was first observed approximately seven months before admission and persisted for some time (four months before admission, 3+; two days before admission, 3+). In addition, the patient complained of lower limb edema about four months before admission and subsequently complained of shortness of breath about two months prior to admission. Chest X-ray taken two days before admission revealed bilateral pleural effusion, and the patient was referred to our hospital with suspected nephrotic syndrome.

Her vital signs included a blood pressure of 143/92 mmHg, a heart rate of 91 beats/min, a body temperature of 36.6°C, a respiratory rate of 18 breaths/min, a blood oxygen saturation level of 96% without oxygen administration, and Glasgow Coma Scale score of E4 V5M6. A physical exami-
nation revealed pitting edema of both the upper and lower extremities and coarse crackles on chest auscultation. An electrocardiogram showed an irregular rhythm consistent with AF. Blood tests revealed hypoproteinemia (4.4 g/dL), hypoalbuminemia (1.1 g/dL), and dyslipidemia. Urine tests revealed nephrotic-range proteinuria (11.9 g/gCre), a low serum albumin (1.1 g/dL), and dyslipidemia. Urine tests revealed proteinuria (3+), casts Fe (2+), proteinuria (3+), and radial arteries was performed on hospital day 9, revealing filling defects in these arteries and a mural thrombus. Further, echocardiography performed before the biopsy revealed no evidence of left atrial expansion or thrombus in the left atrium. Therefore, rivaroxaban was scheduled to be resumed a week after the biopsy.

When the patient was at a high risk for hemorrhagic adverse events following the biopsy due to the presence of several hemorrhagic risk factors (use of anticoagulants, being a woman, and multiple punctures during the biopsy). At the same time, she was also at risk for thromboembolism due to the presence of several thrombotic risk factors (anticoagulant discontinuation, nephrotic syndrome, and initiation of oral prednisolone). It was initially estimated that the risk of bleeding was higher than that of thromboembolism, since there have been no reports of thromboembolism due to anticoagulant discontinuation following a renal biopsy. Furthermore, echocardiography performed before the biopsy revealed no evidence of left atrial expansion or thrombus in the left atrium. Therefore, rivaroxaban was scheduled to be resumed a week after the biopsy.

However, the patient suddenly complained of numbness and pain in her right forearm on hospital day 8. A physical examination revealed coldness of her right forearm and a faint pulse in her right brachial and radial arteries. Additional blood testing revealed a high level of D-dimer (14.8 μg/mL). Acute brachial arterial embolic occlusion was suspected, although we had never experienced thromboembolism following a renal biopsy. Contrast-enhanced CT revealed filling defects in these arteries and a mural thrombus in the abdominal aorta (Fig. 1a-c).

Emergent endovascular thrombectomy at the right brachial and radial arteries was performed on hospital day 9, resulting in successful recanalization and improvement of the

| Blood cell count | CA19-9 | 4.6 U/mL | MPO-ANCA | 1.8 IU/mL |
|------------------|--------|----------|-----------|-----------|
| WBC              | 8,230 /μL | Protein C activity | ≥151 % | PR3-ANCA | 2.1 IU/mL |
| RBC              | 4.87x10⁶ /μL | Protein S activity | 52 % | Transferrin | 128 mg/dL |
| Hb               | 16.3 g/dL | Protein profiling | | Bence-Jones protein | Negative |
| Hct              | 46.5 % | Alb | 34.7 % | Urinalysis | pH | 6.5 |
| Pt               | 34.7x10⁴ /μL | α₁- globulin | 4.7 % | | |

Blood chemistry

| CRP | 0.47 mg/dL | β- globulin | 13.5 % | 11.9 g/gCre |
| TP | 4.4 g/dL | γ- globulin | 20.8 % | Occult blood | (2+) |
| Alb | 1.1 g/dL | Coagulation | | RBC | 50-99 /HPF |
| AST | 35 U/L | PT-INR | 0.98 | WBC | Negative |
| ALT | 20 U/L | APTT | 28.1 sec | Granular casts | Few/LPF |
| LDH | 351 U/L | Fibrinogen | 621.1 mg/dL | Fatty casts | Few/LPF |
| T-Bil | 0.4 mg/dL | Immunochemistry | | Dysmorphic RBC | Positive |
| BUN | 11.2 mg/dL | IgG | 834 mg/dL | Cre | 30.2 mg/dL |
| Cre | 0.84 mg/dL | IgA | 294 mg/dL | NAG | 11.5 U/L |
| Na | 137 mEq/L | IgM | 142 mg/dL | β₂MG | 629 μg/L |
| K | 3.7 mEq/L | C3 | 101.9 mg/dL | Bence-Jones protein | Negative |
| Cl | 101 mEq/L | C4 | 32.1 mg/dL | Transferrin | 37.0 mg/dL |
| Ca | 8.0 mg/dL | CH50 | 57.9 U/mL | IgG | 33.8 mg/dL |
| Total cholesterol | 331 mg/dL | ANA | ×40 titer | |
| Triglycerides | 260 mg/dL | Anti-ds DNA antibody | 20.0 IU/mL | |
| LDL cholesterol | 197 mg/dL | Anti-CL IgG antibody | Negative | |
| HDL cholesterol | 82 mg/dL | Anti-CL-β₂GP1 complex antibody | Negative | |
| HbA1c (NGSP) | 5.6 % | Lupus anticoagulant | Negative | |
| CEA | 7.6 mg/mL | |

ANA: antinuclear antibody, ds DNA: double stranded deoxyribonucleic acid, CL: cardiolipin
numbness and pain in the right forearm. A dose of 5,000 U of heparin was administered intravenously, and rivaroxaban was resumed. Follow-up CT recorded on hospital day 11 revealed no evidence of arterial embolic occlusion in the right arm, although the mural thrombus in the abdominal aorta remained. No hemorrhagic adverse events or further thromboembolisms were detected after resumption of rivaroxaban. Additional laboratory testing to evaluate thrombogenic factors reported low activity of protein S and a slightly elevated serum level of anti-double stranded deoxyribonucleic acid antibody (anti-dsDNA antibody) but no elevation in serum levels of antiphospholipid antibodies. However, we deemed the probability of inherited protein S deficiency or systemic lupus erythematosus (SLE) to be low, since the low activity of protein S could be explained by massive protein loss in urine related to nephrotic syndrome, and there were no symptoms or renal pathological findings specific to SLE.

Proteinuria improved with glucocorticoid therapy, and complete remission from nephrotic syndrome was observed on hospital day 32. The patient was discharged on hospital day 36. A schematic illustration of the clinical course is shown in Fig. 2.

**Discussion**

The present report describes a patient with nephrotic syndrome in which anticoagulant discontinuation contributed to acute brachial arterial embolic occlusion following a renal biopsy. This case suggests the possibility that anticoagulant discontinuation following a renal biopsy can result in thromboembolism in patients with thrombotic risk factors who have taken anticoagulants. Coagulopathy is a rare complication of renal biopsies (3, 4), and to our knowledge, this is the first report to describe thromboembolism associated with anticoagulant discontinuation following a renal biopsy.

Most complications of renal biopsies are associated with bleeding (1). Therefore, periprocedural anticoagulant discontinuation is required when patients are biopsied. Several recommendations for the periprocedural management of anticoagulants have been published; however, in clinical practice, anticoagulants are empirically resumed after renal biopsies, depending on the evaluated hemorrhagic and thrombotic risks. According to the previous version of the renal biopsy guideline published by Japanese Society of Nephrology in 2004, anticoagulants should be discontinued for one or two weeks after renal biopsies because of delayed hemorrhagic complications (5, 6). However, in the new version of the guideline, published in 2020, anticoagulants should be resumed one or two days after renal biopsies or when medical tests reveal no evidence of aggravated renal bleeding (7). This recommendation was based on three reasons. First, a questionnaire survey revealed that approximately 60% of specialized medical centers in Japan performed periprocedural management where anticoagulants were resumed one or two days after renal biopsies or once biopsied patients were under hemorrhagic control (7). Second, the Japanese
guidelines for gastrointestinal endoscopy for patients taking antithrombotic drugs recommend that patients undergoing anticoagulant therapy be treated as a high-risk group for thromboembolisms (8). Third, according to the guidelines of the American College of Chest Physicians, recommended perioperative management includes continuing therapeutic-dose heparin until 4 to 6 hours before surgery and resuming it 48 to 72 hours after surgery in patients at high risk of thromboembolism (9). Despite these recommendations, the length of periprocedural anticoagulant discontinuation varies among medical institutions, as no high-quality clinical trials exist regarding the periprocedural management of anticoagulants.

In the present case, the timing of the resumption of rivaroxaban presented a dilemma because the patient was at high risk of both hemorrhagic and thrombotic events. Hemorrhagic risk factors following renal biopsies include the renal function, underlying renal diseases, patients’ medical background, and procedure-related factors. Risk factors associated with the renal function are chronic kidney disease, acute kidney injury, and rapidly progressive glomerulonephritis (10-13). Risk factors associated with underlying renal diseases are thin basement membrane syndrome, vasculitis, acute interstitial nephritis, and amyloidosis, which confer a high risk (13, 14). Risk factors associated with the medical background of the patients are hypertension (≥160/100 mmHg), female sex, anemia, low platelet count, and the use of antithrombotic drugs (15). The main risk factor associated with the procedure itself is a high number of punctures (≥4) (16); the size of the biopsy needle does not contribute to major hemorrhagic complications (17). Hemorrhagic risk factors in the present case were a female sex, use of anticoagulants, and frequent punctures, suggesting that this case had a relatively high risk of bleeding. In contrast, the thrombotic risk factors in this case were anticoagulant discontinuation, nephrotic syndrome, and the use of oral glucocorticoids, suggesting a high risk for thromboembolism.

In general, anticoagulation therapy for AF is based on the CHADS2 score, and either a direct oral anticoagulant or warfarin is chosen. A high CHADS2 score is associated with a high annual incidence rate of stroke, and anticoagulant discontinuation results in the development of stroke in patients with AF with a high CHADS2 score (18, 19). In the present case, the patient had AF with a CHADS2 score of 1 and had been receiving rivaroxaban for a considerable time; therefore, periprocedural discontinuation of rivaroxaban may have increased her thrombotic risk. Furthermore, nephrotic syndrome and the use of oral glucocorticoids may contribute to the development of thromboembolism. According to previous reports, approximately 25% of cases of nephrotic syndrome are complicated by thromboembolism (20), with annual incidence rates of venous and arterial embolism of 1.02% and 1.48%, respectively (21). The use of glucocorticoids, especially their initiation, is associated with an increased thrombotic risk (22). In the present case, additional blood tests to evaluate other thrombogenic factors revealed low serum levels of protein S and a slightly elevated serum level of anti-dsDNA antibody. However, the probability of inherited protein S deficiency, SLE, or antiphospholipid antibody syndrome was deemed low. Given the previous reports and clinical findings above, acute arterial embolic occlusion may have developed due to the simultaneous presence of anticoagulant discontinuation, nephrotic syndrome, and initia-
tion of glucocorticoid therapy.

Therefore, it is better to initiate glucocorticoid therapy without performing a renal biopsy when immune-mediated renal diseases are suspected in anticoagulated patients, since renal biopsies in these patients are associated with a high risk of hemorrhagic and thrombotic events. The present patient was provisionally diagnosed with minimal change disease because of the highly selective proteinuria; hence, it would have been desirable to evaluate the reactivity of glucocorticoid therapy in this patient without performing a renal biopsy in order to avoid the occurrence of hemorrhagic and thrombotic events.

Two clinical issues in the present case report remain to be addressed. First, thromboembolism may occur in the natural course of nephrotic syndrome, regardless of anticoagulant therapy discontinuation; indeed, approximately 25% of nephrotic syndrome cases develop thromboembolism (20). However, anticoagulant discontinuation was very likely an exacerbating factor for thromboembolism in this case, as supported by previous reports of anticoagulant discontinuation-associated thromboembolism in patients with AF (18, 23). In those reports, AF patients who discontinued anticoagulants had a higher incidence and poorer prognosis of thrombotic events than those who did not discontinue anticoagulants. Furthermore, most thrombotic events occurred within one or two weeks after anticoagulant discontinuation. Indeed, acute brachial arterial embolic occlusion occurred four days after anticoagulant discontinuation in this case, suggesting that anticoagulant discontinuation may have contributed to the pathophysiology, in addition to nephrotic syndrome. Second, whether or not the early resumption of rivaroxaban was clinically appropriate in this case, as recommended in the new version of the renal biopsy guideline published by the Japanese Society of Nephrology in 2020, is unclear (7). There have been no high-quality clinical studies concerning the safety of the early resumption of anticoagulants following renal biopsies; whether or not anticoagulants should be resumed in the early postprocedural period in patients undergoing renal biopsies thus remains controversial.

In conclusion, we present a case of nephrotic syndrome in which periprocedural anticoagulant discontinuation contributed to acute brachial arterial embolic occlusion following a renal biopsy. This case suggests that anticoagulant discontinuation-associated thromboembolism can develop after renal biopsy, although coagulopathy is generally rare as such a complication. If immune-mediated renal diseases are suspected in patients with a relatively high risk of thrombotic events who have taken anticoagulants, physicians should consider initiating glucocorticoid therapy without a renal biopsy to avoid hemorrhagic and thrombotic events.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We would like to thank Editage (www.editage.com) for the English language editing.

Research involving Human Participants and/or Animals:

This manuscript does not contain any studies with human participants performed by any of the authors.

Informed consent: Informed consent was obtained from all participants included in the study.

References

1. Bakkash K, Schramm KM, Annam A, Brown M, Kondo K, Lindquist JD. Complications of percutaneous renal biopsy. Semin Intervent Radiol 36: 97-103, 2019.
2. Xu DM, Chen M, Zhou FD, Zhao MH. Risk factors for severe bleeding complications in percutaneous renal biopsy. Am J Med 2017; 135: 230-235, 2017.
3. Dara T, Lohr J. Disseminated intravascular coagulation following percutaneous renal biopsy. Am J Nephrol 11: 343-344, 1991.
4. Nagata H, Sato M, Ogura M, et al. Coagulopathy as a complication of kidney biopsies in paediatric systemic lupus erythematosus patients with antiphospholipid syndrome. Nephrology (Carlton) 23: 592-596, 2018.
5. Hirakata H, Morozumi K, Ishimura E, et al. “Jinseiken gaidobukku” [Guidebook of the renal biopsy]. 1st ed. Tokyo Igakusha, Tokyo, 2004: 44 (in Japanese).
6. Shima N, Hayami N, Mizuno H, et al. Arteriovenous fistula-related renal bleeding 5 days after percutaneous renal biopsy. CEN Case Rep 8: 280-284, 2019.
7. Ubara Y, Tsuruya K, Katsuno T, et al. “Jinseiken gaidobukku” [Guidebook of the renal biopsy]. 2nd ed. Tokyo Igakusha, Tokyo, 2020: 54-55 (in Japanese).
8. Kato M, Ueno N, Hokimoto S, et al. “Kouksesennyaku fukuyousha ni taiosuru shoukaki nishiko shiryou gaidorainn” [Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment]. Gastroenterol Endosc 59: 1547-5158, 2017.
9. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: E326S-E350S, 2012.
10. Lees JS, McQuarrie EP, Mordi N, Geddes CC, Fox JG, Mackinnon B. Risk factors for bleeding complications after nephrologist-performed native renal biopsy. Clin Kidney J 10: 573-577, 2017.
11. Shidham GB, Siddiqi N, Beres JA, et al. Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology (Carlton) 10: 305-310, 2005.
12. Korbet SM, Gashi CN, Evans JK, Whittier WL. Risk of percutaneous renal biopsy of native kidneys in the evaluation of acute kidney injury. Clin Kidney J 11: 610-615, 2018.
13. Fisi V, Mazik I, Degrell P, et al. Histological Diagnosis determines complications of percutaneous renal biopsy: a single-center experience in 353 patients. Kidney Blood Press Res 35: 26-34, 2012.
14. Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 9: 40-45, 2005.
15. Vilet JMM, Martinéz MAM, Sanchez BMC, Ibargüengoitia MC, Rotter RC. Buenrostro LEM. Simple risk score for prediction of haemorrhagic complications after a percutaneous renal biopsy. Nephrology (Carlton) 23: 523-529, 2018.
16. Chikamatsu Y, Matsuda K, Takeuchi Y, et al. Quantification of bleeding volume using computed tomography and clinical complications after percutaneous renal biopsy. Clin Kidney J 10: 9-15, 2017.
17. Tønдел C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol 7: 1591-1597, 2012.

18. Vene N, Mavri A, Gubenšek M, et al. Risk of thromboembolic events in patients with non-valvular atrial fibrillation after dabigatran or rivaroxaban discontinuation - data from the Ljubljana Registry. PLoS One 11: e0156943, 2016.

19. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 61: 651-658, 2013.

20. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome - associated thromboembolic disease. Clin J Am Soc Nephrol 7: 513-520, 2012.

21. Mahmoodi BK, Kate MKT, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 117: 224-230, 2008.

22. Johannesdottir SA, Puh6 EH, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study. JAMA Intern Med 173: 743-752, 2013.

23. Park JH, Han SW, Lee KY, et al. Impact of non-vitamin K antagonist oral anticoagulant withdrawal on stroke outcomes. Front Neurol 9: 1095, 2018.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).